48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients.
Positive Trikafta results set a benchmark of efficacy for future CF therapies. Photo by filadendron/E+ via Getty Images.
On 18 May, at the 2026 American Thoracic Society (ATS) international conference, during a poster session, a single-centre, observational cohort study was presented with results for elexacaftor/tezacaftor/ivacaftor (ETI) that focused on clinical and laboratory parameters in people with cystic fibrosis (pwCF) carrying at least one F508del allele.
The therapy, also known by its brand name Trikafta/Kaftrio, is a triple combination therapy from Vertex Pharmaceuticals and is formulated to improve the function of the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR modulator therapies have been instrumental in transforming the cystic fibrosis (CF) treatment paradigm, particularly demonstrating improvements in lung function and in overall quality of life.
The latest set of positive long-term data presented, with a particular focus on haemoglobin (HbA1c), liver function tests and immunoglobulin G (IgG) levels, will continue to bolster Trikafta’s dominant position in the CF market and strengthen the therapy’s evidence base to enable more informed decision-making and patient monitoring as part of the broader post-authorization efficacy studies and market access framework.
